Tibolone

Selective tissue estrogen activity regulator utilization in postmenopausal women

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tibolone is a safe and effective therapy in early menopausal women. Its indications for use are several. It is effective in treating vasomotor symptoms. It causes some endometrial bleeding in the first few months, but this decreases during the first year more than on estrogen. Despite the bleeding, endometrial biopsies show no evidence of endometrial stimulation and there has been no evidence of endometrial hyperplasia or cancer after 2 years. It also has the advantage over selective estrogen receptor modulators (SERMs) of increasing the vaginal maturation value. At the 1.25 mg dose, tibolone is highly effective in preventing bone loss in women in the early postmenopausal years, and early reports suggest that this dose can prevent fractures in older women. In general, tibolone is well tolerated, and there has been no increase in the risk of cardiovascular events or venous thrombosis in younger postmenopausal women. In women in their mid-60s, tibolone increases the risk of stroke in the 1.25 mg dose, and although it appears to reduce fractures, the risk/benefit ratio of the 1.25 mg dose has to be taken into consideration in older women.

Original languageEnglish
Title of host publicationMenopause
PublisherElsevier Inc.
Pages847-852
Number of pages6
ISBN (Print)9780123694430
DOIs
StatePublished - 2007

Fingerprint

tibolone
Estrogens
Hemorrhage
Endometrial Hyperplasia
Selective Estrogen Receptor Modulators
Endometrial Neoplasms
Venous Thrombosis
Stroke
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Dentistry(all)
  • Medicine(all)

Cite this

Tibolone : Selective tissue estrogen activity regulator utilization in postmenopausal women. / Archer, David F.; Gallagher, John Christopher G.

Menopause. Elsevier Inc., 2007. p. 847-852.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{fbaf3c3487734982a12326616ed0f32e,
title = "Tibolone: Selective tissue estrogen activity regulator utilization in postmenopausal women",
abstract = "Tibolone is a safe and effective therapy in early menopausal women. Its indications for use are several. It is effective in treating vasomotor symptoms. It causes some endometrial bleeding in the first few months, but this decreases during the first year more than on estrogen. Despite the bleeding, endometrial biopsies show no evidence of endometrial stimulation and there has been no evidence of endometrial hyperplasia or cancer after 2 years. It also has the advantage over selective estrogen receptor modulators (SERMs) of increasing the vaginal maturation value. At the 1.25 mg dose, tibolone is highly effective in preventing bone loss in women in the early postmenopausal years, and early reports suggest that this dose can prevent fractures in older women. In general, tibolone is well tolerated, and there has been no increase in the risk of cardiovascular events or venous thrombosis in younger postmenopausal women. In women in their mid-60s, tibolone increases the risk of stroke in the 1.25 mg dose, and although it appears to reduce fractures, the risk/benefit ratio of the 1.25 mg dose has to be taken into consideration in older women.",
author = "Archer, {David F.} and Gallagher, {John Christopher G.}",
year = "2007",
doi = "10.1016/B978-012369443-0/50074-0",
language = "English",
isbn = "9780123694430",
pages = "847--852",
booktitle = "Menopause",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Tibolone

T2 - Selective tissue estrogen activity regulator utilization in postmenopausal women

AU - Archer, David F.

AU - Gallagher, John Christopher G.

PY - 2007

Y1 - 2007

N2 - Tibolone is a safe and effective therapy in early menopausal women. Its indications for use are several. It is effective in treating vasomotor symptoms. It causes some endometrial bleeding in the first few months, but this decreases during the first year more than on estrogen. Despite the bleeding, endometrial biopsies show no evidence of endometrial stimulation and there has been no evidence of endometrial hyperplasia or cancer after 2 years. It also has the advantage over selective estrogen receptor modulators (SERMs) of increasing the vaginal maturation value. At the 1.25 mg dose, tibolone is highly effective in preventing bone loss in women in the early postmenopausal years, and early reports suggest that this dose can prevent fractures in older women. In general, tibolone is well tolerated, and there has been no increase in the risk of cardiovascular events or venous thrombosis in younger postmenopausal women. In women in their mid-60s, tibolone increases the risk of stroke in the 1.25 mg dose, and although it appears to reduce fractures, the risk/benefit ratio of the 1.25 mg dose has to be taken into consideration in older women.

AB - Tibolone is a safe and effective therapy in early menopausal women. Its indications for use are several. It is effective in treating vasomotor symptoms. It causes some endometrial bleeding in the first few months, but this decreases during the first year more than on estrogen. Despite the bleeding, endometrial biopsies show no evidence of endometrial stimulation and there has been no evidence of endometrial hyperplasia or cancer after 2 years. It also has the advantage over selective estrogen receptor modulators (SERMs) of increasing the vaginal maturation value. At the 1.25 mg dose, tibolone is highly effective in preventing bone loss in women in the early postmenopausal years, and early reports suggest that this dose can prevent fractures in older women. In general, tibolone is well tolerated, and there has been no increase in the risk of cardiovascular events or venous thrombosis in younger postmenopausal women. In women in their mid-60s, tibolone increases the risk of stroke in the 1.25 mg dose, and although it appears to reduce fractures, the risk/benefit ratio of the 1.25 mg dose has to be taken into consideration in older women.

UR - http://www.scopus.com/inward/record.url?scp=84882926511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882926511&partnerID=8YFLogxK

U2 - 10.1016/B978-012369443-0/50074-0

DO - 10.1016/B978-012369443-0/50074-0

M3 - Chapter

SN - 9780123694430

SP - 847

EP - 852

BT - Menopause

PB - Elsevier Inc.

ER -